Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Please wear the patch not longer than 8 hours
In order to produce an orally available GLP-1R agonist, increased efforts have been directed towards the development of small molecules
Synapse database indicates that 3 patents have been filed for this peptide: GEP44 elicits Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets, thus revealing the counteracting effects of Y1-R and GLP-1R agonism
Insurance Accepted We accept most insurance, but encourage you to talk directly to your insurance about specific coverage, many do not cover weight loss in general
Potential Benefits and Current Research Evidence Phase 2 trial data support retatrutide's efficacy for weight reduction in obesity, but 5-Amino-1MQ has no published human clinical trials and its benefits in people remain unproven
US$ 25.45
US$ 27.44
US$ 28.11
